Efficacy and safety of a basal insulin + 2‐3 oral antihyperglycaemic drugs regimen versus a twice‐daily premixed insulin + metformin regimen after short‐term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open‐label, randomized controlled BEYOND‐V trial

Author:

Pan Qi1,Li Yijun2,Wan Hailong3,Wang Junfen4,Xu Binhua5,Wang Guoping6,Jiang Chengxia7,Liang Li8,Feng Wei9,Liu Jingcheng9,Wang Ting9,Zhang Xia9,Cui Nan9,Mu Yiming2ORCID,Guo Lixin1ORCID,

Affiliation:

1. Department of Endocrinology, Beijing Hospital National Center of Gerontology Beijing China

2. Department of Endocrinology The First Medical Center of Chinese PLA General Hospital Beijing China

3. Department of Endocrinology Panjin Central Hospital Panjin China

4. Department of Endocrinology Second Hospital of Shijiazhuang Shijiazhuang China

5. Department of Endocrinology Harbin the First Hospital Harbin China

6. Department of Endocrinology Second Affiliated Hospital of Baotou Medical College Baotou China

7. Department of Endocrinology The Second People's Hospital of Yibin Yibin China

8. Department of Endocrinology People's Hospital of Liaoning Province Shenyang China

9. Medical Department Sanofi Shanghai China

Funder

Sanofi China Investment Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3